Foreword: After Actavis: Seven Ways Forward

67 Rutgers University Law Review 543 (2015)

13 Pages Posted: 9 Sep 2015

Date Written: June 10, 2015

Abstract

The Supreme Court’s decision in FTC v. Actavis is one of the most important antitrust decisions in the modern era. This symposium in the Rutgers University Law Review, which accompanied a live conference at the University of San Francisco Law School, consists of seven articles that provide guidance on Actavis.

This foreword introduces the articles, which (1) explain why courts have misconstrued Actavis (Davis & McEwan); (2) articulate the “Actavis inference” and show how it reveals errors in court opinions and scholarship (Edlin, Hemphill, Hovenkamp, & Shapiro); (3) offer a set of jury instructions that courts can use in reverse-payment cases (Sorenson & Shadowen); (4) explain why brand promises not to introduce their own generics constitute payment (Carrier); (5) show how state law can target reverse-payment settlements (Johnson); (6) explain why the Noerr-Pennington doctrine does not immunize reverse-payment settlements (Garcia); and (7) demonstrate how Actavis can apply beyond the pharmaceutical industry (Ghosh).

Keywords: patent, antitrust, drugs, pharmaceuticals, Actavis, drug patent settlements, reverse payments, Actavis inference, jury instructions, authorized generics, Cipro, Noerr-Pennington

JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38

Suggested Citation

Carrier, Michael A., Foreword: After Actavis: Seven Ways Forward (June 10, 2015). 67 Rutgers University Law Review 543 (2015). Available at SSRN: https://ssrn.com/abstract=2656007

Michael A. Carrier (Contact Author)

Rutgers Law School ( email )

217 North Fifth Street
Camden, NJ 08102-1203
United States
856-225-6380 (Phone)
856-225-6516 (Fax)

Register to save articles to
your library

Register

Paper statistics

Downloads
67
Abstract Views
632
rank
343,332
PlumX Metrics